Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ritter Pharmaceuticals Inc    RTTR

RITTER PHARMACEUTICALS INC

(RTTR)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:32am EST

Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28

LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan will be the subject of an expert call to be held on February 20, 2019 at 1:00 PM ET/10:00 AM PT.

The call can be accessed via the following link: https://slingshotinsights.com/projects/965

Dr. Chey will be discussing:

  • The unmet medical need and target population for a potential pharmaceutical grade treatment of lactose intolerance (LI)
  • How LI is diagnosed in practice, the shortcomings of current treatment options and the role the microbiome plays in LI and the mechanism of action of RP-G28.
  • Insights regarding the ongoing, phase 3 clinical trial of RP-G28 including his thoughts on trial design, treatment benefit assessment and probability of success.

Ritter Pharmaceuticals expects to achieve major milestones in 2019, including the completion and data readout of its first pivotal phase 3 trial in lactose intolerance which is expected in the second half of 2019. In December 2018, the Company announced that it had reached the halfway-mark for enrollment in this trial. The 525-subject multicenter, randomized, double-blind, placebo-controlled, parallel-group study continues to enroll on-time. Persons interested in participating in the Liberatus study may receive more information by visiting www.clinicaltrials.gov (NCT03597516) or by visiting www.liberatusstudy.com/clinical-research.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. (www.ritterpharma.com, @RitterPharma) develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 is in Phase 3 clinical development with its first Phase 3 clinical trial, known as “Liberatus,” currently underway. The Company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including: gastrointestinal diseases, cancer, metabolic, and liver disease.

About Dr. William Chey

Dr. Chey is Nostrant Collegiate Professor of Gastroenterology & Nutrition Sciences, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at Michigan Medicine. He also serves as a member of the Board of Trustees of the American College of Gastroenterology, the Board of Directors of the Rome Foundation and a member of the Advisory Board of the International Foundation of Functional GI Disorders. Dr. Chey has authored more than 300 manuscripts, reviews and book chapters, and he was the Co-Editor-in-Chief of the American Journal of Gastroenterology from 2010 to 2015. He has been elected to “Best Doctors” since 2001 and “America’s Top Doctors” since 2009. Dr. Chey has been inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean’s Outstanding Clinician Award, was inducted into the League of Research Excellence at the University of Michigan and has received the Distinguished Clinician Award from the American Gastroenterological Association. Dr. Chey received his B.A. from the University of Pennsylvania and medical degree and training in internal medicine at the Emory University School of Medicine, completing his fellowship in gastroenterology at the University of Michigan.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Any statements contained herein that do not describe historical facts are forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Ritter cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

Contacts
Investor Contact:
John Beck
310-203-1000
john@ritterpharma.com

Media Contact:
Jules Abraham
CoreIR
917-885-7378
julesa@coreir.com

ritter.jpg


© GlobeNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RITTER PHARMACEUTICALS INC
02/12Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February ..
GL
01/24RITTER PHARMACEUTICALS : to Present at Noble Capital Markets' Fifteenth Annual I..
AQ
01/23Ritter Pharmaceuticals To Present at Noble Capital Markets' Fifteenth Annual ..
GL
2018RITTER PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continu..
AQ
2018RITTER PHARMACEUTICALS : Reaches Halfway Mark for Enrollment in Pivotal Phase 3 ..
AQ
2018RITTER PHARMACEUTICALS : Reaches Halfway Mark for Enrollment in Pivotal Phase 3 ..
AQ
2018Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3..
GL
2018CONSOLIDATED RESEARCH : 2018 Summary Expectations for E*TRADE Financial, Ballant..
AQ
2018RITTER PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
2018RITTER PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fina..
AQ
More news
Financials ($)
Sales 2018 -
EBIT 2018 -15,7 M
Net income 2018 -15,6 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 3,47 M
Chart RITTER PHARMACEUTICALS INC
Duration : Period :
Ritter Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 7,50 $
Spread / Average Target 1 140%
EPS Revisions
Managers
NameTitle
Andrew J. Ritter President, CEO, Secretary & Director
Ira E. Ritter Executive Chairman & Chief Strategic Officer
John W. Beck Chief Financial Officer
Diane J. Plotkin Vice President-Clinical Development
Noah J. Doyle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RITTER PHARMACEUTICALS INC0.83%3
GILEAD SCIENCES6.11%87 436
VERTEX PHARMACEUTICALS12.08%48 081
REGENERON PHARMACEUTICALS9.37%45 520
GENMAB-5.01%9 438
SAREPTA THERAPEUTICS INC26.87%9 252